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Family cytokines and il-18 
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Pathways of nK cell activation
Carolyn M. Nielsen† , Asia-Sophia Wolf † , Martin R. Goodier and Eleanor M. Riley*
Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and 
Tropical Medicine, London, UK
Studies to develop cell-based therapies for cancer and other diseases have consistently 
shown that purified human natural killer (NK) cells secrete cytokines and kill target 
cells after in vitro culture with high concentrations of cytokines. However, these assays 
poorly reflect the conditions that are likely to prevail in  vivo in the early stages of an 
infection and have been carried out in a wide variety of experimental systems, which 
has led to contradictions within the literature. We have conducted a detailed kinetic and 
dose–response analysis of human NK cell responses to low concentrations of IL-12, 
IL-15, IL-18, IL-21, and IFN-α, alone and in combination, and their potential to synergize 
with IL-2. We find that very low concentrations of both innate and adaptive common γ 
chain cytokines synergize with equally low concentrations of IL-18 to drive rapid and 
potent NK cell CD25 and IFN-γ expression; IL-18 and IL-2 reciprocally sustain CD25 and 
IL-18Rα expression in a positive feedback loop; and IL-18 synergizes with FcγRIII (CD16) 
signaling to augment antibody-dependent cellular cytotoxicity. These data indicate that 
NK cells can be rapidly activated by very low doses of innate cytokines and that the 
common γ chain cytokines have overlapping but distinct functions in combination with 
IL-18. Importantly, synergy between multiple signaling pathways leading to rapid NK 
cell activation at very low cytokine concentrations has been overlooked in prior studies 
focusing on single cytokines or simple combinations. Moreover, although the precise 
common γ chain cytokines available during primary and secondary infections may differ, 
their synergy with both IL-18 and antigen–antibody immune complexes underscores their 
contribution to NK cell activation during innate and adaptive responses. IL-18 signaling 
potentiates NK cell effector function during innate and adaptive immune responses by 
synergy with IL-2, IL-15, and IL-21 and immune complexes.
Keywords: cD25, antibody, il-2, il-15, synergy
inTrODUcTiOn
Natural killer (NK) cells are classically regarded as innate lymphocytes that, by cytotoxicity and 
cytokine production, are among the earliest responders to damaged, transformed, or infected host 
cells. In the context of infection, they may directly lyse infected cells that no longer express self 
MHC Class I, mediate antibody-dependent cellular cytotoxicity (ADCC) of opsonized cells, or 
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secrete pro-inflammatory cytokines, such as IFN-γ, to activate 
phagocytes. During primary infection in a naive host, NK cells 
are activated by cytokines and contact-dependent signals from 
antigen-presenting cells [reviewed in Ref. (1)]; during secondary 
infection in a primed host, these innate signals are augmented 
by IL-2 from antigen-specific T helper cells (2–6) and by IgG 
immune complexes cross-linking FcRγIII (CD16) on the NK cell 
surface (7).
The precise cocktails of innate cytokines that most efficiently 
activate NK cells in response to any given pathogen, and how 
these cytokines synergize with adaptive responses, such as IL-2 
and antibody to optimize the initial response to infection, are 
poorly described. Although numerous studies have reported 
NK cell activation by specific cytokines, they have tended to 
use very high concentrations of individual cytokines or com-
binations of cytokines, at a single concentration, to activate 
isolated populations of NK cells over rather long periods of 
time. For example, Aste-Amezaga et  al. (8) demonstrated 
synergy between 1 ng/ml IL-12 and 100 IU/ml IL-2 for IFN-γ 
secretion from purified, B cell lymphoma-activated NK cells; 
Fehniger et al. (9) found that IL-12, IL-15, or IL-18 alone did 
not induce IFN-γ but that IFN-γ was produced by positively 
selected human NK cells after 24 h stimulation with 10 U/ml 
(approximately 2  ng/ml) IL-12 in combination with either 
100 ng/ml IL-18 or 100 ng/ml IL-15; Son et al. (10) observed 
proliferation, CD25 upregulation, IFN-γ production, and cyto-
toxic activity in purified NK cells cultured for three days with 
6 IU/ml IL-2 plus 1000 ng/ml IL-18; Trotta et al. (11) observed 
IFN-γ secretion from positively selected NK cells after 24  h 
stimulation with 10 ng/ml IL-12 plus either 100 ng/ml IL-18 or 
10 μg/ml anti-CD16; and Leong et al. (12) described upregula-
tion of CD25 (and subsequent enhanced responsiveness to 
IL-2) among purified NK cells cultured for 16 h with 50 ng/ml 
IL-18 plus either 100 ng/ml IL-15 or 10 ng/ml IL-12.
Although these studies, and others (13–16), produce a con-
sistent picture of purified NK cells being able to proliferate and 
respond functionally to high concentrations of cytokines over 
periods of 16–72 h and are valuable in the context of develop-
ing NK cell-based therapies for cancer and other diseases, they 
provide little insight into the very early contribution that NK cells 
may make during infection. Indeed, there are no published stud-
ies that have systematically evaluated the kinetics, dose–response, 
and synergistic interactions leading to rapid and potent NK cell 
responses under conditions that mimic events early in primary 
infection. Similarly, there are limited data on the interaction 
between innate cytokines and components of the adaptive 
immune response to predict how NK cells might respond during 
secondary and subsequent infections.
In this study, we have conducted a detailed dose–response 
analysis of human NK cell CD25 and IFN-γ responses to IL-12, 
IL-15, IL-18, IL-21, and IFN-α at 6 and 18 h, and looked for synergy 
between low concentrations of these cytokines and IL-2. We have 
also investigated the capacity of IL-18 to synergize with FcRγIII 
(CD16) signaling to drive degranulation (CD107a) responses, 
in addition to CD25 and IFN-γ upregulation. Importantly, our 
assays have been carried out on unselected NK cells within 
peripheral blood mononuclear cells, in order to avoid inadvertent 
activation of NK cells during the purification process and in order 
to better reflect the cellular environment in which early responses 
to infection take place in vivo. Our data reveal potent and rapid 
activation of NK cells at cytokine concentrations that are orders 
of magnitude lower (and thus more physiologically relevant) than 
previously described. We also observe synergy between members 
of the common γ chain (γc) cytokine family, which includes IL-15, 
IL-2, and to a lesser extent IL-21, and IL-18, at exceedingly low 
concentrations; synergy between IL-18 and FcRγIII signaling 
in initiation of ADCC reactions; and synergistic, reciprocal 
upregulation of IL-18 receptor (IL-18Rα) and the high affinity 
IL-2 receptor (CD25) by IL-18 and IL-2 in an effective positive 
feed back loop.
In summary, these data indicate that NK cells can be very rap-
idly activated by exceedingly low doses of innate cytokines, such 
as might be found within minutes or hours at the site of infection, 
and can be further potentiated by adaptive immune responses 
(T cell IL-2 and antigen–antibody immune complexes) that are 
expected to occur upon re-infection.
MaTerials anD MeThODs
study subjects
Volunteers were recruited from among staff and students at the 
London School of Hygiene and Tropical Medicine. All subjects 
gave written consent under a protocol for recruitment of blood 
donors approved by the LSHTM ethics committee (reference # 
5520) to provide ≤50 ml venous blood.
PBMc Preparation and culture
PBMCs were isolated from heparinized venous blood on a 
Ficoll–Hypaque gradient and cryopreserved in liquid nitrogen. 
Before use, PBMCs were thawed into complete medium [RPMI 
1640, supplemented with 100  U/ml penicillin/streptomycin 
and 20 mM l-glutamine (Life Technologies) and pooled 10% 
human AB plasma], washed, and rested for a minimum of 
30 min before use.
PBMCs (2 × 105/well) were cultured for 6 or 18 h in 5% CO2 at 
37°C at in 96-well U-bottom plates (Nunc) in complete medium 
with or without varying concentrations and combinations of 
recombinant human IL-2, IL-12, IL-15, IFN-α, IL-21 (all from 
PeproTech), IL-18 (R&D Biosystems), or inactivated influenza 
virus H3N2 (1 μg/ml, NIBSC). GolgiStop (containing Monensin, 
1/1500 concentration, BD Biosciences) and GolgiPlug (contain-
ing brefeldin A, 1/1000 final concentration, BD Biosciences) were 
added after 3 and 15 h (in 6 and 18 h cultures, respectively) in 
experiments where intracellular IFN-γ was a read-out. Similarly, 
anti-CD107a antibody (A488-conjugated, BD Biosciences) was 
included in the medium for the entirety of cell culture when 
CD107a upregulation was a read-out.
For activation via CD16 cross-linking, 96-well flat-bottom 
plates (Nunc) were coated with anti-human CD16 (BD 
Biosciences) or an isotype-matched control antibody (mIgG1κ, 
BD Biosciences) overnight at 4°C. Plates were washed with 
sterile PBS before addition of 4 × 105 PBMC per well. Cells were 
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FigUre 1 | il-18 and il-15 both independently drive cD25 but interact differently with il-2. PBMCs were stimulated for 6 or 18 h in vitro and upregulation 
of NK cell surface expression of CD25 was measured in response to Med (medium alone), IL-2, IL-12, IL-15, IL-18, or IL-21. Representative flow cytometry plots 
show gating of CD3−CD56+ NK cells and surface expression of CD25 on unstimulated and IL-15-stimulated NK cells (50 ng/ml) (a). CD25 expression on NK cells 
was measured after stimulation with Med, IL-2, IL-12, IL-15, IL-18, or IL-21 (concentrations in nanograms per milliliter as labeled) for 6 h (B) or 18 h (c) (n = 6–22, 
data from two to three experiments). Concentrations in boxes indicate those used in following graphs. CD25 expression on NK cells was also measured after 
stimulation with a titration of IL-2 (0, 5, and 50 ng/ml) in combination with IL-12 (12.5 pg/ml), IL-15 (0.75 ng/ml), and/or IL-18 (10 ng/ml) for 18 h (D) (n = 7–8, data 
from two experiments). CD25 expression on NK cells was also measured following stimulation with 5 ng/ml IL-21 in combination with 5 ng/ml IL-2, 0.75 ng/ml 
IL-15, or 10 ng/ml IL-18 after 18 h (e) (n = 8, data from one experiment). CD25 expression after stimulation for 18 h with a combination of IL-18 (10 ng/ml) and γc 
cytokines was summarized to facilitate comparison between IL-2 (5 ng/ml), IL-15 [0.75 ng/ml; both from (D)], and IL-21 [5 ng/ml; from (e)] (F) (n = 7–8, data from 
one to two experiments). Box plots show the 5th to 95th percentile range. Data were analyzed using paired Wilcoxon signed-rank tests [(B,c,F) no lines; lowest 
concentration compared to Med, (e) capped lines; IL-2/IL-18 and IL-15/IL-18 compared to IL-18 alone, (F)] or ANOVA tests for linear trend for trend analysis across 
increasing cytokine concentrations including Med [(B–D), uncapped lines]. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
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harvested after 6 or 18 h. GolgiStop, GolgiPlug, and anti-CD107a 
were used, as described above.
Flow cytometry
PBMCs were stained in 96-well U-bottom plates, as described 
previously (6). Briefly, cells were stained with fluorophore-labeled 
antibodies to cell surface markers then fixed, permeabilized 
(Cytofix/Cytoperm, BD Biosciences), and stained for intracel-
lular molecules. The following monoclonal antibodies were 
used: anti-CD3-V500, anti-CD57-e450, anti-CD56-PECy7, 
anti-CD107a-A488, anti-IFN-γ-allophycocyanin, anti-CD16-
allophycocyanin-H7, anti-CD16-allophycocyanin, anti-CD25-
PerCPCy5.5, anti-IL-18Rα-PE, and anti-IL-18Rα-FITC (all BD 
or e-Biosciences). Anti-IL-12Rβ2 (R&D Systems) was conjugated 
to PerCP/Cy5.5 in-house (EasyLink PerCP/Cy5.5® Abcam). Cells 
were acquired on an LSRII flow cytometer (BD Biosciences) using 
FACSDiva software. Data analysis was performed using FlowJo v10 
(Tree Star). Gating strategies are detailed in figure legends, with 
gates set on unstimulated cells (medium alone or isotype controls, 
with no cytokine stimulation) and applied in a standard format.
statistical analyses
Statistical analysis of flow cytometry data was performed using 
Prism 6 (GraphPad), as specified in figure legends. Data were 
excluded when the gated cell subset contained fewer than 100 cells. 
Paired Wilcoxon signed-rank tests were used to compare responses 
between stimulation conditions and ANOVA tests for linear trend 
were used to analyze cytokine titrations. Formal tests for synergy 
using regression analysis with an interaction term, and linear 
regression adjusting for confounding factors were performed in 
STATA (V.14.0). All statistical tests are two-sided ****p ≤ 0.0001, 
***p <  0.001, **p <  0.01, *p <  0.05. Sample sizes are stated in 
figure legends.
resUlTs
common γ chain Family cytokines 
synergize with il-18 to Drive cD25 
expression on nK cells
PBMCs were stimulated with increasing concentrations of IL-2, 
IL-12, IL-15, IL-18, or IL-21, and NK cell surface expression of 
CD25 was measured after 6 or 18 h (Figures 1A–C). Upregulation 
of CD25 is of interest as a marker of NK cell activation and, more 
specifically, increased sensitivity to IL-2; indeed, NK cell produc-
tion of IFN-γ in response to picomolar levels of IL-2 has been 
shown to be CD25 dependent (12). The highest cytokine con-
centrations tested reflect those widely used as positive controls 
by ourselves (5, 6, 17) and others; cytokines were then titrated to 
concentrations at least fivefold lower than the lowest previously 
described effective concentration.
4Nielsen et al. IL-18 Potentiates NK Activation
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IL-15 and IL-18 each, independently, drive CD25 expression 
in a dose- and time-dependent manner. Significant CD25 
expression could be detected within 6  h among cells cultured 
with cytokine concentrations as low as 0.75  ng/ml IL-15 and 
10 ng/ml IL-18 (Figure 1B) but CD25 expression was markedly 
higher after 18  h for both cytokines and evident at the lowest 
cytokine concentrations tested (0.75  ng/ml IL-15 and 5  ng/ml 
IL-18) (Figure 1C). For IL-15, this is 6-fold lower than the previ-
ously described minimal concentration (14, 16) for upregula-
tion of CD25, and 10- to 1000-fold lower than previously used 
concentrations of IL-18 (12, 15). Incubation of PBMC with IL-2, 
IL-12, and IL-21 induced minimal, albeit statistically significant, 
expression of CD25 on NK cells at 18 h, but not at 6 h.
To investigate potential synergies between cytokines in driv-
ing CD25 expression on NK cells, PBMCs were stimulated with 
combinations of IL-12, IL-15, and IL-18, with or without vary-
ing concentrations of IL-2, to model early NK cell activation in 
response to primary pathogen infection (innate cytokines only, 
no IL-2) and secondary infection (innate cytokines plus IL-2 
from memory CD4+ T cells). We selected the lowest concentra-
tions of IL-12 and IL-15 that had been tested singly (12.5 pg/ml 
and 0.75 ng/ml, respectively) and, for consistency with our own 
previously published work (5, 6, 17), we used the middle concen-
tration of IL-18 (10 ng/ml). The middle concentration of IL-21 
(5 ng/ml), an adaptive γc cytokine, was selected to permit later 
comparisons with IL-2.
Consistent with the data presented in Figure  1B, CD25 
expression was very low after 6 h, and there was no significant 
evidence of synergism between cytokines (data not shown). 
However, after 18 h, the data clearly showed synergy between 
IL-18 and IL-2 in driving NK cell CD25 expression (trend 
analysis p <  0.0001 for IL-18 in combination with increasing 
concentrations of IL-2) with 5 ng/ml IL-2 in combination with 
10  ng/ml IL-18 giving CD25 expression levels equivalent to 
those seen with 50 ng/ml IL-18 alone (Figures 1C,D). Although 
adding IL-12 to a cocktail of IL-2 plus IL-18 did not further 
enhance CD25 expression, including a low concentration of 
IL-12 (0.0125  ng/ml) in the cultures did permit detection of 
a modest IL-2 dose response (Figure  1D) and much higher, 
though less physiological, concentrations of IL-12 (1–10 ng/ml) 
do synergize with IL-18 to drive CD25 expression (Figure S1 
in Supplementary Material) (12, 18). There was also strong 
evidence that IL-15 synergizes with IL-18 to enhance NK cell 
CD25 expression (Figure  1F, test for interaction IL-15 and 
IL-18, p = 0.009).
By contrast, IL-15-driven CD25 upregulation was partially 
inhibited by IL-2: there was a trend for the proportion of NK 
cells expressing CD25 to decrease with increasing concentrations 
of IL-2 in all cytokine combinations that included IL-15, with a 
statistically significant impact observed in NK cells stimulated 
with IL-15 plus IL-18 (median without IL-2 = 38.1% vs. median 
with high concentration IL-2  =  29.0%; linear test for trend, 
p = 0.04; Figure 1D).
In a separate set of experiments, we also tested IL-21 and 
IFN-α for their ability to synergize with IL-2, IL-15, and IL-18 
to drive CD25 expression on NK cells. There was no evidence 
that IFN-α alone induced CD25 expression nor did it enhance 
CD25 expression in combination with other cytokines (Figure S2 
in Supplementary Material). However, IL-21 in combination 
with IL-2, IL-15, or, in particular, IL-18 significantly enhanced 
CD25 expression compared to these cytokines alone (Figure 1E). 
Indeed, there was clear evidence of synergy between IL-21 and 
IL-18 driving CD25 expression (Figure 1F, test for interaction 
IL-21 and IL-18, p < 0.0001).
In summary, these data indicate that at least three differ-
ent cytokines that signal via the common γ chain (CD132) 
can individually synergize with the IL-18 pathway leading to 
rapid upregulation of CD25 expression on NK cells, and at 
much lower cytokine concentrations than previously appreci-
ated (Figure 1F). As IL-15 and IL-18 are produced primarily 
by dendritic cells, monocytes, and macrophages, and as IL-2 
and IL-21 are primarily T cell-derived, these combinations 
of cytokines allow for very early NK cell activation  –  when 
cytokine concentrations are still extremely low  –  via both 
innate and adaptive immune pathways. Moreover, there is 
evidence of homeostatic regulation of NK cell activation via 
γc cytokines, as illustrated by inhibition of IL-15-driven CD25 
upregulation by IL-2.
common γ chain cytokines synergize 
with il-18 to Drive rapid and extensive 
iFn-γ Production by nK cells
Upregulation of CD25 primes NK cells for enhanced subsequent 
responses to IL-2 (12) but is not, in itself, a read-out of NK cell 
effector function. We have therefore characterized the effect of 
combining low concentrations of different cytokines on IFN-γ 
production, assessed by intracellular staining after incubation of 
PBMC with increasing concentrations of individual cytokines or 
cytokine combinations (Figure 2).
Increasing concentrations of IL-2, IL-12, IL-15, or IL-18 (but 
not IL-21) each, individually, induced significant IFN-γ produc-
tion by NK cells at 18 h, although the proportions of IFN-γ+ cells 
rarely exceeded 10% even at the highest cytokine concentrations 
(Figure  2B). However, combining IL-18 (at a concentration of 
10 ng/ml), with as little as 5 ng/ml IL-2 (which alone did not drive 
IFN-γ) not only induced IFN-γ in much higher proportions of 
NK cells (>20%) but did so within 6 h of incubation (Figure 2C). 
Although this interaction appears additive at 6 h (test for interac-
tion, p = 0.22) by 18 h the interaction is highly synergistic (test 
for interaction, p = 0.006), possibly as a result of IL-18 induced 
upregulation of the high affinity IL-2R.
In contrast to what we observed for CD25 expression, 
there was no evidence of antagonism or competition between 
γc cytokines in their induction of NK cell IFN-γ. On the con-
trary, there was evidence of additive or synergistic interactions 
between γc cytokines with increasing concentrations of IL-2 
modestly but significantly enhancing NK cell IFN-γ responses 
to IL-15 + IL-18 (Figures 2C,D). Low concentrations of IL-15 
(Figures  2C,D) and IL-21 (Figure  2E) also enhanced IL-18-
induced NK cell IFN-γ production, but to a lesser extent than 
IL-2 (Figures  2C,D,F). Although IL-15 plus IL-18 has previ-
ously been shown to enhance NK cell IFN-γ, as measured by 
ELISA, the effects described here were apparent at an IL-15 
A B
C D
E F
FigUre 2 | il-15 and il-18 can synergize to drive iFn-γ in absence of il-12 or il-2. PBMCs were stimulated for 6 or 18 h in vitro and production of 
intracellular IFN-γ by NK cells was measured in response to Med (medium alone), IL-2, IL-12, IL-15, IL-18, or IL-21. Representative flow cytometry plots show gating 
of CD3−CD56+ NK cells and percentage of CD56+ cells that are positive for intracellular IFN-γ on unstimulated and IL-12-stimulated NK cells (5 ng/ml) (a). IFN-γ 
production by NK cells was measured after stimulation with Med, IL-2, IL-12, IL-15, IL-18, or IL-21 (concentrations in nanograms per milliliter as labeled) for 18 h  
(B) (n = 4–9, data from one to three experiments). Concentrations in boxes indicate those used in following graphs. IFN-γ production by NK cells was also 
measured after stimulation with a titration of IL-2 (0, 5, and 50 ng/ml) in combination with IL-12 (12.5 pg/ml), IL-15 (0.75 ng/ml), and/or IL-18 (10 ng/ml) for 6 h  
(c) or 18 h (D) (n = 7–8, data from two experiments). IFN-γ production by NK cells was also measured following stimulation with 5 ng/ml IL-21 in combination with 
5 ng/ml IL-2, 0.75 ng/ml IL-15, or 10 ng/ml IL-18 after 18 h (e) (n = 8, data from one experiment). IFN-γ expression after stimulation for 18 h with a combination of 
IL-18 (10 ng/ml) and γc cytokines was re-plotted to facilitate comparison between IL-2 (5 ng/ml), IL-15 [0.75 ng/ml; both from (D)], and IL-21 [5 ng/ml; from (e)] for 
18 h (F) (n = 7–8, data from one to two experiments). Box plots show the 5th to 95th percentile range. Data were analyzed using paired Wilcoxon signed-rank tests 
[(B): no lines; lowest concentration compared to Med; (e) capped lines] or ANOVA tests for linear trend for trend analysis across increasing cytokine concentrations 
including Med [(B–D), uncapped lines]. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. n ≥ 8, other than for IL-21 titration (B) where n = 4.
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concentration (0.75  ng/ml) markedly lower than previously 
described (5 ng/ml) (14).
Again, as for CD25 expression, we found no evidence of 
a role for IFN-α in NK cell IFN-γ production (Figure S2 in 
Supplementary Material); this is in contrast to published data 
(19). Low concentrations of IL-12 (0.0125 ng/ml) – alone or in 
combination with IL-2 or IL-21 – had minimal effects on IFN-γ 
production (Figures 2C–E), but did enhance IFN-γ production 
in combination with IL-15 and IL-18 at later time points. High 
concentrations of IL-12 (≥1 ng/ml) synergized strongly with IL-18 
to drive both IFN-γ and CD25, although we suggest that these do 
not reflect physiological conditions (Figure S1 in Supplementary 
Material) (9, 11, 12, 15, 20). Overall, however, as little as 5 ng/ml 
IL-2 in combination with low concentrations of IL-18 (10 ng/ml) 
and IL-12 (12.5 pg/ml) was the optimal combination for NK cell 
IFN-γ induction at 18 h.
In summary, therefore, γc cytokines (IL-2, IL-15, and IL-21) in 
combination with IL-18 induce very rapid and extensive IFN-γ 
production by NK cells (Figure 2F). Although IL-2 seems to be the 
most potent of these, at least at the cytokine concentrations tested, 
the ability of IL-15 to augment IFN-γ production offers a route for 
rapid, innate activation of NK cells prior to the differentiation of 
IL-2 secreting T cells. Of interest, given the very large body of work 
describing IFN-γ induction by combinations of IL-12 and IL-18, γc 
6Nielsen et al. IL-18 Potentiates NK Activation
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cytokines synergize with IL-18 at extremely low concentrations. It 
is possible therefore that, in vivo, IL-12 may contribute to NK cell 
IFN-γ production when γc cytokines are lacking, such as during 
primary exposure (when IL-2 from antigen-specific T cells may be 
limiting) or later in infection when IL-15 signaling is reduced by 
changes in receptor expression (21, 22).
il-18 signaling sustains il-18rα 
expression on nK cells
As IL-18 alone is able to induce both CD25 and IFN-γ expres-
sion within 6  h (Figures  1B and 2C), we hypothesized that 
maintaining the capacity for IL-18 signaling might be required 
for optimal NK cell activation. Thus, the sustained or enhanced 
expression of the IL-18R may contribute to the synergy between 
IL-18 and γc cytokines. To determine whether, and if so which, 
cytokines regulate IL-18R expression, NK cell surface expres-
sion of IL-18Rα [CD218a, the receptor component required for 
signaling (23)] was measured after 6 or 18 h of PBMC culture 
with IL-2, IL-12, IL-15, IL-18, IL-21, or IFN-α, alone and in com-
bination (Figure 3; Figure S2 in Supplementary Material). It was 
immediately obvious that resting levels of IL-18Rα expression 
are extremely variable between donors with the proportion of 
resting NK cells expressing the receptor varying from approxi-
mately 20% to >80% (Figures 3B,C). Polymorphisms affecting 
DNA methylation within the promoter region of IL18R1, the 
gene encoding IL-18Rα, and subsequent transcription of the 
gene have been reported and may in part explain this variation 
(24, 25) and we have previously observed lower levels of IL-18Rα 
expression in human cytomegalovirus (HCMV)-infected indi-
viduals than in HCMV-uninfected individuals (6). Despite this 
inter-individual variation, resting levels of IL-18Rα expression 
are very high in comparison to resting levels of the high affinity 
IL-2R (as defined by expression of the IL-2Rα chain, CD25; see 
Figures 1B,C) and fully functional IL-12R (as defined by expres-
sion of IL-12R-β2; see Figure S2 in Supplementary Material) and 
may explain the very rapid (within 6 h) NK cell response to exog-
enous IL-18 (Figures 1B and 2C). Indeed, we observed a weak 
but statistically significant correlation between resting levels of 
NK cell IL-18Rα expression and upregulation of CD25 follow-
ing IL-18 stimulation [n = 18, 50 ng/ml IL-18, linear regression 
(adjusting for use of PE- and FITC-conjugated anti-IL-18Rα) 
R2 = 0.241, p = 0.046].
Contrary to previously published data indicating that IFN-α 
(13) and IL-12 (9, 11, 13, 20) can individually induce IL-18R 
mRNA (9, 13), IL-18Rα protein expression (11), or IL-18R 
expression (20) in human NK cells, and that IL-12/STAT4 
signaling induces IL-18Rα expression in mice (26, 27), we 
found no increase in surface expression of IL-18Rα in response 
to increasing concentrations of either IFN-α (Figure S2 in 
Supplementary Material) or IL-12 (Figure 3B) with or without 
IL-2 (Figure 3C). There are several likely explanations for this 
discrepancy. For example, in previous studies, exogenous IL-2 
was routinely added to NK cell cultures and IFN-α was used 
at much higher concentrations (13); NK cells were stimulated 
with very high concentrations of IL-12 (9, 11); IL-18R mRNA 
was assessed rather than IL-18R protein (9, 13); NK cells were 
purified by positive selection which may, in itself, contribute to 
subsequent activation (9, 11); or components of the IL-18R other 
than IL-18Rα were measured (9, 13, 20). Nevertheless, our data 
suggest that at physiological concentrations, IL-2, IL-12, and 
IFN-α have little, if any, effect on IL-18Rα expression. We also 
observed no effect of IL-21 on IL-18Rα expression (Figure S2 in 
Supplementary Material).
By contrast, we found clear evidence of concentration-
dependent upregulation of NK cell IL-18Rα expression in 
response to IL-15 alone and IL-18 alone (Figures  3B,C). Ten 
nanograms per milliliter of IL-18 were sufficient to upregulate 
IL-18Rα within 6 h (Figure 3B) (p = 0.0010) and this effect was 
sustained at 18 h (Figure 3C) (p = 0.0003). IL-15 had no effect on 
IL-18Rα expression at 6 h, but as little as 0.75 ng/ml IL-15 was suf-
ficient to upregulate IL-18Rα expression by 18 h (Figures 3B,C) 
(p =  0.019). Overall, IL-15 and IL-18 each increased the pro-
portion of NK cells expressing IL-18Rα by approximately 15% 
(median percentage of IL-18Rα+ NK cells: 50.1% medium only; 
64.6% with 50 ng IL-18; 66.8% with 50 ng IL-15). The ability of 
IL-18 to rapidly augment expression of its own receptor is sug-
gestive of a positive feedback loop, allowing for enhanced IL-18 
signaling, continued synergism with other signaling pathways 
and efficient induction of NK cell effector functions in the first 
few hours of infection.
We next considered whether other cytokines might synergize 
with IL-18 to further enhance IL-18Rα expression. Increasing 
concentrations of IL-2, either alone or in combination with IL-12 
or IL-15 had no significant effect on IL-18Rα expression at either 
6 h (not shown) or 18 h (Figure 3D). However, IL-2 modestly but 
significantly enhanced the effects of IL-18 in a dose-dependent 
manner, and there was an additive effect of combining IL-15 
and IL-18 in the absence of IL-2 (Figure 3D). Addition of other 
cytokines to the IL-18 +  IL-2 cocktail did not further enhance 
IL-18Rα expression. Although at the low cytokine concentrations 
used in these experiments (0.0125 ng/ml IL-12, 10 ng/ml IL-18) 
we saw no additive or synergistic effect of adding IL-12 to IL-18, 
at much higher concentrations (5  ng/ml IL-12 and 50  ng/ml 
IL-18) we did observe a significant (p < 0.0001) additive effect 
of these two cytokines increasing IL-18Rα expression (data not 
shown). These data support our contention that IL-18 is the key 
cytokine in initiating and sustaining NK cell responses under 
physiologically relevant conditions such as very early infection, 
and that NK cell responses that can be induced with very high 
(non-physiological) cytokine concentrations in vitro may not be 
relevant in vivo.
In summary, therefore, low concentrations of IL-18 rapidly 
and significantly upregulate the IL-18Rα subunit and this effect 
is augmented by low concentrations of IL-15 and (more sub-
stantially) by IL-2. Given that IL-18 alone is sufficient to induce 
expression of the high affinity IL-2R (Figures 1B,C), it seems that 
IL-18 and IL-2 synergistically and reciprocally upregulate their 
own and each other’s receptors in a potent positive feedback loop. 
The minimal role of low concentrations of IL-12 in this process 
may explain the limited synergies of exogenous IL-12 in the early 
NK cell IFN-γ response (Figure 2).
For completeness, we also examined expression of 
IL-12Rβ2 in response to single cytokines or cytokine 
A B
D
C
FigUre 3 | Positive feedback from il-18 induces il-18r. PBMCs were stimulated for 6 or 18 h in vitro and changes in NK cell surface expression of IL-18Rα 
was measured in response to Med (medium alone), IL-2, IL-12, IL-15, IL-18, or IL-21. Representative flow cytometry plots show gating of CD3+ T cells, CD3−CD56+ 
NK cells, and surface expression of IL-18Rα on unstimulated T cells and NK cells for IL-18Rα-FITC [N.B. as used in (D); IL-18Rα-PE used in (B,c)] (a). IL-18Rα 
expression on NK cells was measured after stimulation with Med, IL-2, IL-12, IL-15, IL-18, or IL-21 (concentrations per milliliter as labeled) for 6 (B) or 18 h (c) 
(n = 7–11 data from one to two experiments). Concentrations in boxes indicate those used in following graphs. IL-18Rα expression on NK cells was also measured 
after stimulation with a titration of IL-2 (0, 5, and 50 ng/ml) in combination with IL-12 (12.5 pg/ml), IL-15 (0.75 ng/ml), and/or IL-18 (10 ng/ml) after 18 h (D) (n = 8, 
data from two experiments). Box plots show the 5th to 95th percentile range. Data were analyzed using paired Wilcoxon signed-rank tests [(B–D) no lines; 
compared to Med] or ANOVA tests for linear trend for trend analysis across increasing cytokine concentrations including Med [(B–D), uncapped lines]. 
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
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combinations (Figure S3 in Supplementary Material). The 
proportion of NK cells expressing IL-12Rβ2 was transiently 
(seen at 6  h but not at 18  h) and very modestly enhanced by 
10–50  ng/ml IL-18 and, in a slightly more sustained fashion, 
by 50  ng/ml IL-15, but the biological relevance of such small 
effects is unclear. There was no effect of exogenous cytokines 
on IL-12Rβ2 expression at the level of individual cells (as 
measured by MFI).
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il-18 synergizes with Fcγriii (cD16) 
signaling to augment nK cell-Mediated 
antibody-Dependent cellular cytotoxicity
After vaccination, or upon secondary infection, circulating 
antigen–antibody complexes binding to FcγRIII (CD16) on NK 
cells can mediate killing of infected cells via ADCC. As our data 
suggest that IL-18, in concert with γc cytokines, enhances adap-
tive and innate pathways of NK cell activation, we wanted to test 
whether ADCC could be augmented by very low levels of NK cell 
activating cytokines, as would be present at the site of infection 
(Figure 4).
We found that IL-18, but not IL-12, IL-15, or IL-21, induced 
rapid (within 6 h) and sustained (persists at 18 h), concentration-
dependent downregulation of CD16 expression at the NK cell 
surface such that cells substantially lost CD16 expression within 
6 h in the presence of 10 ng/ml IL-18 (Figures 4A,B; Figure S2 
in Supplementary Material). We have previously observed that 
cross-linking of CD16 with plate-bound anti-CD16 antibody 
leads to loss of CD16 from the NK cell surface (Goodier, unpub-
lished data), and this is consistent with previous reports of CD16 
downregulation following CD16 ligation (28). Here, we observe 
that the inherent capacity of IL-18 to reduce CD16 expression 
synergizes with the effects of CD16 cross-linking such that after 
6 and 18 h, residual CD16 expression is lower when NK cells are 
cultured with 10 ng/ml IL-18 plus plate-bound anti-CD16 than 
when they are cultured with either anti-CD16 or IL-18 alone 
(Figure 4C). Taken together with data indicating that downregu-
lation of CD16 on CD56dim NK cells in response to either CD16 
cross-linking or to very high concentrations of IL-12 (10 ng/ml) 
plus IL-18 (100 ng/ml) can be blocked with a specific inhibitor 
specific of the metalloprotease ADAM-17 (28), these data raise 
the interesting hypothesis that the IL-18 and the CD16 signaling 
pathways may converge to induce metalloprotease-mediated 
cleavage of CD16 from the cell surface. We could not find any 
evidence that CD16 cross-linking affects expression of IL-18Rα 
(data not shown).
Using cross-linking of cell surface CD16 with plate-bound 
anti-CD16 antibody as a model of ADCC (28), we next deter-
mined the effects of low concentrations of IL-18 on NK cell 
cytotoxicity [assessed using the CD107a degranulation assay 
(29, 30)] as well as on CD25 and IFN-γ responses. Despite the 
very rapid downregulation of CD16 by IL-18 and CD16 cross-
linking (Figures  4B,C), we observed that as little as 10  ng/ml 
IL-18 markedly and very rapidly (within 6  h) augmented NK 
cell degranulation and IFN-γ production in the presence of anti-
CD16 antibody (Figures 4D,E). Furthermore, IL-18 synergized 
with anti-CD16 to enhance CD25 expression at 18 h (Figure 4F; 
test for interaction, p = 0.005). These data demonstrate that IL-18 
can substantially enhance NK cell ADCC responses and also sup-
port the idea that IL-18- and anti-CD16-driven downregulation 
of CD16 expression is a consequence of activation of signaling 
pathways downstream of CD16.
To validate this apparent interaction between IL-18 and 
CD16, PBMCs were incubated for 18 h with or without whole, 
inactivated H3N2 influenza virus in the presence of plasma 
that had previously been shown to contain anti-H3N2 IgG 
and to mediate ADCC [(6); Goodier et al., submitted]. NK cell 
degranulation, CD25, and IFN-γ responses to H3N2 immune 
complexes were compared in the presence or absence of exog-
enous IL-18 (Figure 5). As reported above, IL-18 alone induced 
modest increases in CD107a, CD25, and IFN-γ expression. 
Furthermore, as previously reported for H1N1 virus (6), incuba-
tion of NK cells with H3N2 virus and plasma containing anti-
H3N2 antibodies induced significant degranulation (CD107a 
expression) (Figure 5A), upregulation of CD25 (Figure 5B), and 
production of IFN-γ (Figure 5C). However, as little as 5 ng/ml 
IL-18 in combination with H3N2 and anti-H3N2 was sufficient 
to markedly augment CD107a, CD25, and IFN-γ expression; 
the effects of the combination of IL-18 plus H3N2/anti-H3N2 
were additive for CD107a expression, but synergistic for CD25 
and IFN-γ (Figures 5A–C, tests for interaction, 5 ng/ml IL-18 
and H3N2 for CD107a p = 0.269; CD25 p = 0.002; and IFN-γ 
p = 0.038).
In summary, therefore, IL-18 synergizes with CD16-mediated 
signals to augment NK cell ADCC activity and indicates that 
IL-18 may play an important role in driving NK cell cytotoxicity 
and cytokine production.
DiscUssiOn
The capacity of NK cells to be activated, within minutes or hours, 
by very low concentrations of innate cytokines is integral to their 
role as early responders during infection. Although pathogens 
may, ultimately, be cleared by components of the adaptive 
immune system, NK cells and other innate leukocytes are criti-
cal for initial containment of infection and orchestration of the 
subsequent adaptive response (31).
The role of exogenous cytokines in driving NK cell responses has 
been studied extensively in different contexts, including infection 
and cancer immunotherapy. However, these in vitro experiments 
have, almost exclusively, been carried out with purified NK cells 
stimulated with very high concentrations of cytokines that do not 
reflect the in vivo response, may over-ride natural homeostatic 
mechanisms that regulate the extent and duration of NK cell acti-
vation, and ignore interactions with other immune cells and with 
components of the adaptive immune system. Importantly, few 
studies have evaluated combinations of more than two cytokines 
and none have carefully titrated cytokine concentrations within 
these combinations. Thus, although we have abundant informa-
tion about which cytokines and other signals can, under certain 
conditions, activate NK cells, we have a much less clear picture of 
which signals and which combinations of signals most efficiently 
activate NK cells in physiologically relevant conditions.
In an attempt to conduct a more physiologically relevant 
analysis of NK cell–cytokine interactions, we have conducted a 
systematic analysis of the roles of different cytokines and cytokine 
combinations in NK cell activation and their interaction with 
adaptive immune responses. We have demonstrated that NK 
cells can respond, within hours, to concentrations of cytokines 
that are orders of magnitude lower than previously appreciated 
and that NK cells can integrate signals, synergistically, from mul-
tiple cytokine receptors and FcγRIII, enabling them to respond 
AB
C D
E F
FigUre 4 | il-18 enhances responses to cD16 cross-linking, while simultaneously driving cD16 downregulation. PBMCs were stimulated for  
6 or 18 h in vitro and changes in CD16 mean fluorescence intensity (MFI) of CD16+ NK cells were measured in response to Med (medium alone), IL-12, IL-15, or 
IL-18. Representative flow cytometry plots show gating of CD3−CD56+ NK cells, and surface expression of CD107a or CD16 on unstimulated cells, or CD107a on 
NK cells activated with CD16 cross-linking and 10 ng/ml IL-18 (a). CD16 MFI on CD56dimCD16+ NK cells was measured after stimulation with Med, IL-12, IL-15,  
or IL-18 (concentrations in nanograms per milliliter as labeled) for 6 or 18 h (B) (n = 9–13, data from two to three experiments). For the cross-linking assays (as 
described in the Section “Materials and Methods”), PBMCs were stimulated for 6 or 18 h in vitro with Med (medium alone), α-CD16 or its IgG1 isotype control,  
with (+) or without (−) 10 ng/ml IL-18. CD16 MFI of CD56dimCD16+ NK cells was measured after 6 or 18 h (c) (n = 7–16, data from one to two experiments). 
Surface expression of CD107a (D), intracellular IFN-γ (e), and CD25 (F) was measured on NK cells after 6 or 18 h (n = 7–16, data from one to two experiments). 
Box plots show the 5th to 95th percentile range. Data were analyzed using paired Wilcoxon signed-rank tests [(c–F) capped lines] or ANOVA tests for linear trend 
for trend analysis across increasing cytokine concentrations including Med [(B) uncapped lines]. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
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quickly and effectively to extremely low concentrations of 
pro-inflammatory stimuli.
Our study differs from published work not only in the very low 
concentrations of stimuli used, and the use of multiple cytokines in 
combination, but also in that we have analyzed NK cell responses 
within whole PBMCs (containing other lymphocyte populations 
as well as monocytes, macrophages, and dendritic cells) rather 
than using purified NK cells. Although the use of purified NK 
cells removes extraneous signals and allows the effects of precisely 
controlled cytokine concentrations to be evaluated, this approach 
negates the potential role of secondary cytokine responses and 
cell–cell contact-mediated signals, which may potentiate the 
effect of the test stimulus (1). We fully accept that, in our assays, 
exogenous cytokines might induce other cells in the PBMC 
population to express accessory molecules or produce cytokines 
that augment NK cell responses, and indeed this may explain the 
rather limited contribution of exogenous IL-12 in our assays, but 
we argue that this better reflects the in vivo situation and the true 
potential of NK cells. Both tissue-resident NK cells and circulating 
NK cells that infiltrate inflamed sites will receive co-stimulatory 
signals from myeloid and lymphoid cells present at the site of 
infection, and this interplay between different components of the 
immune system is crucial to rapid containment of infection.
Removing accessory cells from culture abrogates many 
important cell–cell signals; for example, contact between NK 
cells and DCs is required for optimal presentation of IL-15 via 
IL-15-IL-15Rα complexes, reducing the minimally effective 
IL-15 concentration from the nanomolar to picomolar range (32, 
33). Similarly, interactions between NK cells and macrophages 
mediated, for example, by NKG2D and ICAM–LFA-1, are 
required for NK cell activation in numerous infection models 
[(34, 35) and reviewed in Ref. (1, 36)]. In the absence of these 
co-stimulatory signals, responses of isolated NK cells to rather 
high concentrations of exogenous cytokines represent only a 
very incomplete picture of their true potential. Moreover, NK cell 
isolation may, in itself, introduce artifacts. Negative selection with 
agonistic anti-CD3 antibodies risks leaving behind a residue of 
highly activated, cytokine-producing T cells that may confound 
analysis of responses to other cytokines, and positive selection 
of NK cells requires cross-linking of surface receptors that may 
positively or negatively affect the subsequent NK cell response. 
On balance therefore, we suggest that the experiments reported 
here better reflect physiological conditions during early infection 
and provide novel insights into NK cell activation in this context. 
Although circulating NK cells are the only easily accessible 
population in humans, experiments using tissue-resident NK 
cells, such as lung-resident NK cells in the context of influenza 
infection, would also be of interest.
Our data point to IL-18 as the key component of the initial 
inflammatory response that “primes” NK cells to respond to other 
cytokines and to FcγRIII/CD16-mediated signals. In accordance 
with published data (12), we show that 50 ng/ml IL-18 is sufficient 
to induce CD25 expression on >40% of NK cells within 18  h; 
however, we extend these data to reveal significant upregulation 
of CD25 within 6 h at IL-18 concentrations as low as 10 ng/ml. 
Rapid IL-18-induced upregulation of CD25 explains the syner-
gistic interaction we observed between IL-18 and IL-2; this has 
been reported previously but only at IL-18 concentrations that are 
100-fold (10) higher than the concentration used here. Moreover, 
our data extend these findings to demonstrate that synergism 
between IL-18 and IL-2 enhances IFN-γ production (irrespective 
of the presence of IL-12 or IL-15) and we confirmed the impor-
tance of IL-18 in enhancing ADCC responses to influenza virus 
via naturally occurring anti-H3N2 antibodies in normal human 
plasma. Taken together, these data place IL-18 at the interface of 
innate and adaptive activation of NK cells.
A
B
C
FigUre 5 | antibody and il-18 synergism in response to h3n2. 
PBMCs were stimulated for 18 h in vitro Med (medium alone), 5, 10, and 
50 ng/ml IL-18 with or without 1 μg/ml inactivated influenza virus H3N2. 
Responses were measured as the percentage of NK cells expressing surface 
CD107a (a), surface CD25 (B), or intracellular IFN-γ (c) (n = 7–8, data from 
one experiment). Box plots show the 5th to 95th percentile range. Data were 
analyzed with paired Wilcoxon signed-rank tests. ****p < 0.0001, 
***p < 0.001, **p < 0.01, *p < 0.05.
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Our data reveal that γc cytokines are key partners of IL-18 in 
this process. IL-2, IL-15, and IL-21 all signal via the common γ 
chain, CD132, while receptors for IL-2 and IL-15 also share the 
β subunit, CD122 [(21, 37) and reviewed in Ref. (38)]. Although 
IL-2 and IL-15 are often considered functionally interchange-
able as a consequence of their shared STAT5 signaling pathway 
[reviewed in Ref. (38)], we find that resting NK cells are much 
more sensitive to IL-15 than to IL-2. This likely reflects the very 
low levels of expression of the high affinity IL-2Rα (CD25) on 
resting NK cells; once CD25 is upregulated, IL-2 is not only an 
extremely potent inducer of NK cell IFN-γ production but also 
further upregulates its own receptor in an autocrine, positive 
feedback loop. Importantly, however, although IL-15 and IL-18 
both individually and synergistically upregulate CD25 expression, 
and IL-18 subsequently synergizes with IL-2 to increase IFN-γ 
production, there is no such synergy between IL-15 and IL-2. 
Rather, adding IL-2 to any cytokine cocktail-containing IL-15 
reduces CD25 expression and has little if any beneficial effect 
on IFN-γ production. This is consistent with evidence that IL-2 
reduces transcription of IL15RA (22), thereby limiting further 
signaling by IL-15, and may represent an important homeostatic 
mechanism to constrain innately driven NK cell responses once 
an effective adaptive immune response is underway.
Sequential activation through shared receptor components, 
initially by an innate cytokine (IL-15) and thence by an adaptive 
cytokine (IL-2), would provide a mechanism of NK cell activa-
tion that is both efficient and self-limiting, and indeed there is 
evidence suggesting that sequential activation of human NK 
cells with IL-15 and then with IL-2 potentiates STAT5 expres-
sion (12, 21). Moreover, downregulation of IL-15Rα expres-
sion by IL-2 (22) may reduce competition between IL-15Rα 
and IL-2Rα for the β and γ chains, facilitating formation of 
A
B
C
FigUre 6 | rapid il-18 driven activation of nK cells. The schematic shows a proposed model of NK cell activation by IL-18 and its synergies with γc cytokines 
or antigen-antibody immune complexes during primary or secondary immune responses. Within 6 h of stimulation, IL-18 drives IL-18R upregulation and modest 
increases in CD25, IFN-γ and degranulation, as well as downregulation of FcγRIII (CD16) (a). In combination with IL-15 or IL-21 from accessory cells, or with 
T cell-derived IL-2, IL-18 drives much stronger CD25 and IFN-γ responses, measurable at 6 h and peaking at 18 h (B). Antigen-antibody complexes cross-link 
CD16 and synergise with IL-18 to drive ADCC and IFN-γ production after 6 and 18 h (c).
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high affinity IL-2R and thus potentiating IL-2 signaling. 
Competition between IL-2 and IL-15 may extend to the shared 
STAT5 pathway and may explain the lack of competition with 
IL-21 that, although sharing the common γ chain receptor, 
signals via STAT3 (38).
We show that IL-18 also synergizes with IgG/CD16, with 
as little as 10 ng/ml IL-18 enhancing NK cell degranulation and 
IFN-γ production within 6 h. IL-18 has previously been reported 
to enhance IFN-γ production and ADCC following CD16 liga-
tion, albeit only at a 10-fold higher IL-18 concentration than 
employed here (39). The discrepancy between these two studies 
may be explained by the much longer (overnight) incubation 
times used by Srivastava et  al. (39) as we found that IL-18/
anti-CD16-induced responses were well past their peak after 
18 h, possibly because of the very rapid downregulation of CD16 
expression by IL-18 that we also observed. Although downregu-
lation of CD16 by IL-18 has been observed previously (15, 39), 
it was reported only at high IL-18 concentration (100  ng/ml 
or 1  μg/ml) after periods of 1–5  days and the effect was not 
fully quantified. The speed with which CD16 is downregulated, 
the very low concentrations of IL-18 required to induce it, and 
the synergy with CD16 cross-linking have not previously been 
appreciated and may, again, represent a homeostatic control 
mechanism to prevent excessive NK cell cytolytic activity and 
associated tissue damage.
Taken together, our data lead us to propose the following 
model of early NK cell activation (Figure  6). At the start of a 
primary infection, the initial colonizing pathogens induce release 
of constitutively expressed IL-15, activation of constitutively 
expressed IL-18 precursor, and secretion of bioactive IL-18, 
and transcription and translation of IL15 and IL18 by dendritic 
cells and macrophages [reviewed in Ref. (40–42)]. The syner-
gistic interaction of IL-15 and IL-18 rapidly induces NK cells 
to produce IFN-γ (within 6  h); this response may be further 
augmented by IL-12 and is sustained (for at least 18 h) by a posi-
tive feedback loop in which IL-18 sustains expression of IL-18Rα. 
At the same time, induced expression of CD25 allows formation 
of the high affinity IL-2R, priming the NK cells to take part in 
T cell-mediated adaptive immune responses. Later in infection, 
or during re-infection, after the differentiation of antigen-specific 
T helper cells and production of antibodies, IL-18 synergizes with 
IL-2 and with antibody-antigen complexes to enhance ADCC and 
IFN-γ production. The immediate availability of IgG antibodies 
allows ADCC reactions to occur within 5 h (28), and subsequent 
rapid downregulation of FcγRIII/CD16 by IL-18 and/or CD16 
cross-linking brings the reaction to a close, thereby preventing 
immune pathology. As IL-2 signaling commences, downregula-
tion of IL-15Rα and/or competition for β and γ chain receptor 
components inhibits further IL-15 signaling. IL-2Rα expression 
is now sustained by IL-18 and IL-2, further enhancing NK cell 
sensitivity to IL-2 and, in synergy with IL-12, maximizing IFN-γ 
production (12).
In summary, therefore, we have shown that IL-18 synergizes 
with components of both the innate (IL-15, IL-12) and the 
adaptive immune response (IL-2, antibody) to very rapidly 
induce antimicrobial NK cell responses (IFN-γ and ADCC). The 
extremely low concentrations of cytokines that are required for 
this process, and the speed with which it happens, identify IL-18 
as a key “first responder” at the intersection of innate and adaptive 
immune responses to infection.
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